Centogene_Logo.png
CENTOGENE Announces Voting Results of Extraordinary General Meeting
22 févr. 2022 06h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO
08 févr. 2022 06h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer
01 févr. 2022 05h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board
01 févr. 2022 05h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan
01 févr. 2022 05h30 HE | Centogene NV
Enables refocusing on core business of delivering valuable, data-driven insights to patients, and pharmaceutical companies globallyEUR 15 million private placement from leading growth investors and a...
Centogene_Logo.png
CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development
20 janv. 2022 06h30 HE | Centogene NV
CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC using AINPC is a rare genetic disease occurring in...
Centogene_Logo.png
CENTOGENE’s CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World
04 janv. 2022 08h00 HE | Centogene NV
The CentoCloud solution is a cloud-based Software as a Service (SaaS) platform that enables laboratories around the world to analyze, interpret, and report genomic variants, and will be able to...
Centogene_Logo.png
CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Discovery
23 déc. 2021 08h00 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO
20 déc. 2021 08h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Centogene_Logo.png
CENTOGENE Reports Third Quarter 2021 Financial Results
24 nov. 2021 07h35 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...